drugset / Trial / NCT00996983

Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer

NCT00996983 ↗

Phase 2 Unknown 16 enrolled National Cancer Institute, Naples
NaSingle-groupOpen-labelTreatment

Summary

Neuropathic pain is difficult to control because it is only partially sensitive to opioid analgesics, and requires the addition of other therapies such as antidepressants and epileptics. Ziconotide is a drug that is used to treat neuropathic pain in patients who have had inadequate pain control with prior combination of medicines.

Timeline

Start
2009-09
Primary completion
2024-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziconotide Unknown 21.6 ug Intrathecal